NOTE 9 – LOANS

ENvue Consolidated Secured Note

On January 17, 2025, ENvue issued a Consolidated Secured Note (as amended, the “Alpha Note”) in the aggregate principal amount of $2,497 to Alpha, which such Alpha Note was funded in several tranches. The Alpha Note does not bear interest and is secured by Collateral (as defined in the ENvue Note). The aggregate principal amount owed under the Alpha Note was originally due and payable on the earlier of (i) the receipt of shareholder approval by the Company of the Parent Stockholder Matters (as defined in that certain Merger Agreement) and (ii) December 31, 2025. As part of the acquisition accounting, the Company recorded the loan at its fair value of $2,258. The difference between the face value and the fair value was recognized as interest expense over the life of the note. During the year ended December 31, 2025, the Company paid $1,417, toward redeeming the Alpha Note, resulting in an outstanding balance of $1,080.

On March 25, 2026, the Company and Alpha entered into an amendment to a loan to modify the maturity date and to extend it to December 31, 2026. All other terms of the loan remain unchanged As of June 30, 2026, the loan balance was $1,080.

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

(Amounts in thousands except share and per share data)

Convertible Debenture

On February 13, 2025, the Company entered into a Securities Purchase Agreement with Alpha, pursuant to which the Company issued a senior convertible debenture (the “Debenture”) with an initial principal amount of $500, subsequently amended and restated on March 26, 2025 to increase the principal amount to $1,300. The Debenture bore interest at 8.0% per annum and was convertible into shares of Common Stock at a conversion price of $48.906 per share, subject to anti-dilution adjustments. The Company selected the fair value option to account for the Debenture, with changes in fair value recorded in other income (expense) in the consolidated statements of operations.

For the six months ended June 30, 2025, the Company recorded a gain of $58 related to the change in fair value of the A&R Debenture, which was recognized in other income (expense) in the consolidated statements of operations. Interest expense on the A&R Debenture totaled $13 for the six months ended June 30, 2025 and is included within the change in fair value of the Debenture in the consolidated statements of operations.

On May 19, 2025, the Company repaid the A&R Debenture in full. There was no balance outstanding as of June 30, 2026.